Sentis

Quick links to important sections

Sentis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sentis

What is Sentis? Definition and Purpose

Property Description
Active Ingredient Phentermine Hydrochloride
Form Oral Tablets or Capsules
Pharmacological Class Sympathomimetic Amine Anorectic
Common Use Adjunct in the management of exogenous obesity
Origin Synthetic

Sentis is the trade name for a prescription-only medicine containing the active ingredient Phentermine Hydrochloride, which is primarily used as an adjunct for the management of exogenous obesity. It is classified as a sympathomimetic amine anorectic, and its primary pharmacological purpose is to suppress appetite.

As a centrally acting medication, Sentis is also classified as a Central Nervous System (CNS) stimulant with a specialized therapeutic application in weight management. Its use is focused on providing pharmacological support alongside a structured, physician-supervised program of reduced-calorie dieting and increased physical activity. Phentermine is intended only as a short-term intervention to initiate weight loss.


The Composition: Phentermine Hydrochloride and Drug Form

The sole active ingredient in Sentis is Phentermine Hydrochloride, a synthetic compound that is chemically related to the amphetamine class. It is provided for oral administration in the form of tablets or capsules, which can include immediate-release or extended-release variants.

Phentermine is indicated for assisting rapid, early weight loss in patients with obesity. As a single-entity product, it contains only the Phentermine molecule as the pharmacologically active component, relying on solid oral excipients for the structure of the tablet or capsule. The drug's classification as an anorectic is a result of its chemical structure and primary therapeutic action.


How Phentermine Supports Appetite Control

The medicine supports weight management by acting as a potent appetite suppressant, making it easier for patients to feel full and adhere to prescribed dietary restrictions.

This effect occurs because Phentermine influences key neurotransmitters in the brain, particularly in the regions that regulate hunger and satiety, resulting in an indirect-acting sympathomimetic effect. By actively dampening the sensation of hunger, the medicine aids in achieving the crucial caloric deficit required for effective weight reduction. This primary action establishes its role as a supportive tool within a broader, disciplined therapeutic strategy designed to combat obesity.

What side effects are possible with Sentis?

Possible Side Effects and Safety Information

The safety profile for Sentis (Phentermine Hydrochloride) is characterized by effects consistent with its classification as a sympathomimetic amine, primarily involving the Cardiovascular and Central Nervous Systems (CNS). Adverse reactions are officially categorized by the physiological system affected, guiding the understanding of potential risks.


Key Safety Classifications

Classification Domain Officially Documented Characteristics
Cardiovascular & CNS Effects Common documented reactions include tachycardia (increased heart rate), elevated blood pressure, insomnia, dry mouth, and overstimulation.
Serious Adverse Reactions Regulatory documents note the rare but severe risk of Primary Pulmonary Hypertension (PPH) and valvular heart disease. The potential for psychotic episodes is also listed.
Duration-Related Patterns Tolerance to the anorectic effect may develop rapidly within a few weeks. The potential for psychological dependence is associated with prolonged use. Abrupt cessation after high-dose use may result in fatigue.
Safety Restrictions (Contraindications) The medication is officially contraindicated in patients with a history of or current cardiovascular disease (including moderate to severe hypertension), hyperthyroidism, history of drug abuse, or use with MAO Inhibitors.

Population-Specific Notes

Safety is not established for pediatric patients under 16 years of age. Caution is officially advised for older adults due to potential increased sensitivity and the higher likelihood of decreased renal function. As the drug is primarily eliminated by the kidneys, patients with renal impairment may require particular attention.

The official safety information strictly defines the drug's risks within the cardiovascular and central nervous systems, which forms the basis for the specific constraints and contraindications listed in regulatory documents.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Overdosage of Sentis (Phentermine) is officially documented to present with signs of excessive central nervous system (CNS) stimulation, which are often followed by a period of fatigue and depression. Acute manifestations listed in regulatory documents include restlessness, tremors, hyperreflexia, confusion, and panic states. Cardiovascular effects listed include tachycardia, arrhythmia, hypertension, or hypotension. Gastrointestinal symptoms such as nausea, vomiting, and abdominal cramps may also occur.

A severe acute overdose can escalate to life-threatening outcomes, including circulatory collapse, convulsions, and coma, with fatal poisoning typically terminating in these severe neurological events. Long-term (chronic) overexposure is associated with severe dermatoses and a psychosis that is officially documented as clinically similar to schizophrenia.

When to Seek Emergency Help

The presence of severe symptoms such as convulsions, coma, or signs of circulatory collapse requires immediate emergency medical attention. The official management of acute intoxication is defined as largely symptomatic and supportive. Documented procedures to manage severe overdosage include gastric lavage and the administration of barbiturates to control extreme central overstimulation. No specific antidote is named in the official prescribing information, and experience with dialysis methods is stated as inadequate to permit recommendation.

Therapeutic Uses of Sentis

What Sentis Treats: Main Uses and Benefits

Sentis (Phentermine) is commonly used in situations involving systemic imbalance by serving as a short-term pharmacological adjunct to a physician-supervised program of diet and exercise for the management of exogenous obesity and clinically significant overweight. It is applied across domains where additional symptomatic support is needed to achieve a crucial first step in a weight-loss journey.


Targeting Exogenous Obesity and High BMI

This medication is generally considered relevant in conditions involving increased physiological stress, specifically as an adjunct in a weight reduction regimen for the management of exogenous obesity in adult patients. It is indicated for patients with an initial BMI ge 30 kg/m^2, or a BMI ge 27 kg/m^2 in the presence of other risk factors, such as controlled hypertension or diabetes. It is used to provide supportive assistance to initiate weight reduction and may support patients in working toward the long-term goal of easing health risks associated with excess body mass.

Easing Symptoms Related to Excessive Appetite

The primary therapeutic benefit Sentis provides is supportive appetite control, which assists with maintaining a sense of stability when symptoms are more noticeable. It helps address symptom clusters that may become intense or disruptive, specifically persistent hyperphagia (excessive hunger) and the difficulty in feeling satiated after meals. By diminishing these signals, the medicine contributes to improved comfort during periods of heightened symptoms, and may assist patients in making adherence to a prescribed reduced-calorie diet more manageable, thus supporting the caloric deficit relevant to weight management.


Quick Fact: Relief for Excessive Appetite The medicine is commonly used to help manage symptoms related to heightened physiological activity, namely the persistent hunger and intense cravings that complicate weight loss.

The clinical indications for its use are defined by the specific need for appetite control, assistance with dietary adherence, and supporting the process of early weight reduction relevant to medically defined obesity or overweight with comorbidities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Sentis?

Sentis (Phentermine) is officially indicated for use only in adult patients as a short-term adjunct in the management of exogenous obesity, specifically for those who meet defined Body Mass Index (BMI) criteria. Eligibility is strictly governed by authoritative regulatory documents which define absolute exclusions and restrictions.


Populations Contraindicated for Use

Use of this medicine is contraindicated and must be avoided in patients with a history of cardiovascular disease, which includes uncontrolled hypertension, coronary artery disease, stroke, or cardiac arrhythmias. It is also prohibited for individuals with hyperthyroidism, glaucoma, a history of drug abuse, or agitated states. The medicine is also contraindicated during or within 14 days following the administration of a Monoamine Oxidase Inhibitor (MAOI).


Age and Condition-Based Restrictions

Population Group Eligibility Status
Pediatric Patients (le 16 years) Not recommended; safety and effectiveness have not been established.
Older Adults (ge 65 years) Use requires caution, usually starting at the low end of the dosage range.
Pregnancy Contraindicated (Pregnancy Category X).
Lactation Not recommended for nursing mothers.
Renal Impairment Use requires caution, with restricted dosage for severe impairment.

Regulatory documentation strictly defines the eligibility profile, authorizing use only for non-contraindicated adults who meet the specific BMI thresholds.

What should I know about interactions with other medicines?

Interactions with other medicines and products

All officially documented interaction information for Sentis (Phentermine) stems from its sympathomimetic classification, primarily outlining pharmacodynamic effects and mandatory use restrictions found in government regulatory labels.


Official Interaction Statements

Category Restrictions as per Regulatory Documents
Contraindicated Combination Use is contraindicated with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of hypertensive crisis.
Mandatory Separation Rule The use of Phentermine is prohibited during or within 14 days following the administration of any MAOI.
Effect on Antihypertensives Phentermine may decrease the hypotensive effect of Adrenergic Neuron Blocking Drugs.
Effect on Diabetic Control Requirements for the dose of Insulin and Oral Hypoglycemic Medications in diabetic patients may be altered.
Restrictions on Co-use Co-administration with other drug products for weight loss (including prescription, over-the-counter, or herbal products) is not recommended, as safety and efficacy have not been established.
Substance Warning Concomitant use with alcohol may result in an adverse drug reaction.

Interaction Classification Summary

The regulatory profile is structured to enforce safety-critical contraindications and mandatory timing requirements for certain substances. The primary mechanism documented in the label is pharmacodynamic, requiring caution with medicines that affect blood pressure and glycemic control. The official documents state that specific enzyme or transporter-mediated interaction mechanisms are not the formal basis for the classified interaction patterns.

Mechanism of Action

How Sentis Works — Mechanism of Action

Sentis’s core mechanism is based on an engineered Natural Killer (NK) cell utilizing a Logic Gate (OR imes NOT) system for selective cytotoxicity.

Dual Targeting for Robust Cancer Cell Elimination

The activation component operates as an OR gate, where the activating Chimeric Antigen Receptor (aCAR) recognizes and binds to either the CD33 or the FLT3 protein on the AML cell surface. This dual-targeting approach influences the cancer's survival pathways by enabling continued recognition despite antigen down-regulation, which results in a broader reduction of the malignant cell population.

The Inhibitory Signal for Healthy Bone Marrow Function

This mechanism includes a protective component where the inhibitory CAR (iCAR) binds to the Endomucin (EMCN) marker, generating a dominant inhibitory signal that overrides the activating signal. This inhibitory signal results in the sparing of hematopoietic stem and progenitor cells and the maintenance of hematopoietic function (blood cell production).

Dosage and Administration Information

How Sentis is Used: Official Administration Guidelines

Sentis, which contains phentermine hydrochloride, is approved exclusively for oral administration as part of a short-term, comprehensive weight reduction program. Its use is strictly governed by dosing and administration rules.


Administration and Dosage Regimens

The medicine is available in several oral dosage forms, including immediate-release tablets (8 mg and 37.5 mg) and capsules (15 mg, 30 mg, and 37.5 mg). The dosing schedule is defined based on the formulation:

  • A common regimen involves taking one 37.5 mg tablet or capsule once daily, typically before or 1 to 2 hours after breakfast.
  • Alternatively, lower-strength doses (e.g., 8 mg) may be administered three times per day, specifically 30 minutes before each meal.

Administration late in the evening is discouraged to mitigate the potential for sleep interference. Extended-release capsules must be swallowed whole and must not be crushed, broken, or chewed.


Course Duration and Specific Use Constraints

Sentis is designated for short-term use only, as an adjunct to diet and exercise. If the appetite-suppressing effect diminishes over time, indicating the development of tolerance, the medication must be discontinued. Guidelines explicitly state that the dosage should not be increased beyond the maximum recommended limit in this situation.

Dosing rules also address specific populations. Use is generally not recommended for pediatric patients under the age of 16 or 17 years. For individuals with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m^2), the maximum daily dose is restricted to 15 mg. Geriatric dosing should be initiated cautiously at the low end of the adult range.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Single-Agent Research (Drug X)

Research has explored its use in patients presenting with advanced symptoms. Research examined whether study participants treated with the drug showed differences in reported pain levels and evaluated the duration of any reported changes. Data from some studies indicated potential symptom changes, though consistency and duration of these findings were noted as variable.

  • Study Design: Researchers investigated the effects of various dosage levels and explored different conditions for drug administration over the course of the trials.

Research on Combination Therapy (Drug X + Drug Y)

Clinical studies have also evaluated the role of Drug X when used alongside Drug Y.

Phase 3 studies evaluated whether the combination was associated with changes in mobility, with researchers reporting on the observed differences in outcomes compared to Drug X alone. The combined approach also investigated the role of the two agents in the treatment process compared to using Drug X alone.

  • Head-to-Head Studies: Studies compared this treatment to existing therapies, with researchers reporting on the observed differences in outcomes. These studies examined the treatment in adults who had not previously responded to conventional first-line treatments.

Mechanism of Action Research

The drug’s function was explored in studies focusing on its interaction with specific targets. Studies investigated the effects of Drug X combined with Drug Y, with researchers evaluating the role of this approach in management strategies.


Study Population Research

  • Studies have examined its use in diverse adult populations. Research also examined its use in individuals with liver conditions, with study results reporting findings relevant to that population.

Key Studies & References

  1. Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS) (ClinicalTrials.gov record for the key trial)

Frequently Asked Questions (FAQ)

Common questions about Sentis (FAQ)


Q: How does Sentis work?

The active ingredient in Sentis is classified as a sympathomimetic amine anorectic. This means its primary function, according to regulatory documents, is to suppress appetite. The medication achieves this through its actions as a Central Nervous System (CNS) stimulant, which influences the areas of the brain that regulate feelings of hunger and fullness. Other CNS actions or metabolic effects may also be involved in its overall effect.

Q: Is Sentis considered a controlled substance in many places?

Yes. Official regulatory bodies such as the US Drug Enforcement Administration (DEA) classify the active ingredient in Sentis as a Schedule IV controlled substance. This classification is due to the potential for dependence or abuse associated with the drug. Its classification suggests a lower risk compared to Schedule III substances, but its distribution and use are strictly controlled.

Q: What are some common mild side effects people report when starting Sentis?

Official labeling documents detail several common reactions often reported when initiating the medication. These include effects like dry mouth, an unpleasant or metallic taste, and headache. Gastrointestinal effects such as diarrhea or constipation, as well as dizziness, are also documented in the adverse reaction profile.

Q: Does Sentis interact with antidepressant medications?

Regulatory warnings indicate a strict contraindication for use with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of serious complications. The safety of combining it with other antidepressant drug classes, such as Selective Serotonin Reuptake Inhibitors (SSRIs), for weight loss has not been established. Official information indicates the importance of providing a complete list of all medications to a healthcare provider for evaluation.

Q: Does Sentis have known interactions with common over-the-counter pain relievers?

Official labeling primarily warns about known interactions with other substances that affect blood pressure and glycemic control. The official labeling generally advises caution when co-administering with any medication that might affect the cardiovascular system. The importance of informing a healthcare provider about all medicines, including over-the-counter products, is a general caution noted in official materials.

Q: Are there any food or drinks that should be avoided when taking Sentis?

Regulatory warnings explicitly state that the simultaneous use of alcohol may result in an adverse drug reaction. Beyond this, regulatory documents do not list specific dietary restrictions aside from the required reduced-calorie regimen that the drug is meant to supplement. Guidance on specific concerns related to diet and consumption is part of the discussion with a healthcare professional.

Q: Can Sentis affect my ability to drive or operate machinery?

Yes, official product information cautions that the medication may impair a patient's judgment or motor skills. Because of this potential risk, official product information advises caution regarding activities that require mental alertness. This includes tasks such as operating machinery or driving a motor vehicle.

Q: What should I know about combining Sentis with caffeine?

The drug is classified as a central nervous system (CNS) stimulant. Although the official label may not specifically name caffeine, combining Sentis with other stimulants generally carries an increased risk of side effects. These can include elevated heart rate or blood pressure, which are documented adverse reactions for the drug. Discussions regarding all sources of stimulation are a typical part of the medical evaluation process.

Q: Is the brand name Sentis the only available version of this drug?

No. The active ingredient in Sentis is phentermine hydrochloride, a chemical compound that is widely available. This means the drug can be obtained under various brand names, or as a generic prescription drug from numerous manufacturers.

Q: Can Sentis affect the results of certain medical tests?

Regulatory documentation indicates that the medicine can influence certain physiological parameters. For example, it notes that the dosage requirements for insulin and other oral hypoglycemic medications may be altered in diabetic patients. This suggests the drug can impact measurements related to blood sugar or glycemic control.

Q: Is the active ingredient in Sentis well-known or new?

The active ingredient, phentermine hydrochloride, is an established pharmacological compound. Regulatory records show it has a long history of use, with initial approval in the U.S. dating back to 1959. It is therefore a well-known agent in the field of weight management.

Q: What resources provide authoritative information about Sentis research?

Authoritative and verifiable information about the medication's research and safety can be found in official government resources. These include documents like the US Food and Drug Administration (FDA) drug label and the National Institutes of Health (NIH) MedlinePlus. Clinical trial information can also be accessed through official registries.

Q: Is a metallic taste in the mouth a known side effect of Sentis?

Yes. An unpleasant or metallic taste in the mouth is listed in the official labeling as a documented adverse reaction. This specific effect is categorized under the drug's known gastrointestinal side effects.

Q: What happens if a dose of Sentis is missed?

General instructions often describe a protocol for missed doses, such as taking a dose as soon as it is remembered, provided it is not too close to the next scheduled time. The regulatory consensus suggests skipping the dose if it is almost time for the next scheduled dose. Regulatory guidance generally cautions against taking double the amount to compensate for a missed dose.

Q: What is the half-life of Sentis generally reported to be?

Detailed pharmacokinetic data are included in regulatory documentation to describe how the drug is processed by the body. This information, often found in the clinical pharmacology section of the label, provides data on the drug's excretion. The half-life is described as prolonged, often cited in the range of 20 hours, which is consistent with its chemical structure.

Q: Can herbal supplements interfere with Sentis?

The official label strongly advises against co-administration with other products intended for weight loss, which explicitly includes certain herbal products. This warning is in place because the safety and efficacy of these combinations have not been formally established in studies. The importance of the prescribing doctor being aware of all supplements being taken is noted in official documentation.

Q: Is it possible to have an allergic reaction to Sentis?

Yes. Official labeling lists allergic reactions as possible adverse reactions associated with the drug. Specific reactions noted include urticaria, which is a common medical term for hives or a rash.

Q: Why is continuous monitoring sometimes recommended when taking Sentis?

Official guidelines emphasize careful evaluation and monitoring, especially of blood pressure and heart rate, due to the drug's profile. This is driven by its known association with rare but serious cardiovascular side effects. These include conditions like primary pulmonary hypertension (PPH) and valvular heart disease.

Q: Does Sentis affect hormonal balance?

The adverse reaction profile includes effects categorized under the Endocrine system, which is responsible for hormonal balance. Specifically, regulatory documents list changes in libido and impotence as possible documented effects.

Q: What does research say about Sentis's effect on mood?

The official adverse reaction list documents several Central Nervous System (CNS) effects that relate to mood and behavior. These include feelings such as euphoria, dysphoria, and restlessness. In rare cases, the regulatory profile notes the potential for psychotic episodes at recommended doses.

How should Sentis be stored and disposed of?

How to Store and Dispose of Sentis?

The official storage conditions for Sentis (phentermine) are defined by strict regulatory requirements to maintain product integrity and safety.

Storage Requirements

The medication must be stored at controlled room temperature, specifically between 20 C and 25 C. The container must be kept tightly closed and stored away from excess heat and moisture (such as a bathroom). It is mandatory to store Sentis out of the reach of children and in a safe place to prevent misuse, theft, or accidental ingestion.

Disposal Instructions

Expired or unused Sentis should be disposed of by following official guidelines. The preferred method is to use a community drug take-back program. If this is not an option, the medication must be mixed with an undesirable substance (like dirt or coffee grounds) and placed in a sealed container before being thrown into the household trash. Sentis is not on the list of medications approved to be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sentis found in:

A-Z Index: